Efficacy and safety of finerenone in diabetic kidney disease: Latin American experience from FINDKDLATAM trial

doi:10.5527/wjn.v15.i1.115933

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 1

This Article

(33)

(48)

(0)

(1088)

(2)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Nephrol. Mar 25, 2026; 15(1): 115933
Published online Mar 25, 2026. doi: 10.5527/wjn.v15.i1.115933

Table 4 Behavior of baseline paraclinical parameters stratified by drug use, median (interquartile rage)

	Baseline
RASSI + SGLT2i (n = 151)
HbA1c	7.5 (6.8-8.1)
eGFR	44 (35-55)
ACR	288 (156-454)
SBP	142 (130-157)
DBP	79 (70-81)
Potassium	4.4 (4.1-4.6)
SGLT2i alone (n = 75)
HbA1c	7.8 (6.8-8.2)
eGFR	32 (28-40)
ACR	458 (270-900)
SBP	145 (130-150)
DBP	80 (70-86)
Potassium	4.4 (4.1-4.6)
GLP-1 + SGLT2i (n = 49)
HbA1c	7.7 (7.0-8.1)
eGFR	32 (28-44)
ACR	644 (321-950)
SBP	145 (135-160)
DBP	75 (70-86)
Potassium	4.4 (4.0-4.7)
RASSI alone (n = 40)
HbA1c	7.2 (6.6-8.0)
eGFR	46 (34-57)
ACR	266 (161-351)
SBP	145 (131-160)
DBP	79 (72-81)
Potassium	4.4 (4.0-4.8)
RASSI + GLP-1 + SGLT2i (n = 18)
HbA1c	7.1 (6.7-9.0)
eGFR	45 (39-59)
ACR	289 (173-523)
SBP	144 (120-156)
DBP	77 (70-86)
Potassium	4.3 (4.0-4.6)
Finerenone alone (n = 8)
HbA1c	7.5 (5.4-7.7)
eGFR	30 (25-55)
ACR	714 (300-1387)
SBP	133 (127-170)
DBP	78 (73-90)
Potassium	4.8 (4.3-5.0)

RASSI: Renin-angiotensin-system inhibitors; SGLT2i: Sodium-glucose cotransporter inhibitor; GLP-1: Glucagon-like peptide-1; HbA1c: Glycated hemoglobin A1c; eGFR: Estimated glomerular filtration rate; ACR: Albuminuria/creatinuria ratio; SBP: Systolic blood pressure; DBP: Diastolic blood pressure.

Full Size Table

Citation: Arnedo RD, Polo VS, Garcia JB, Gutiérrez JF, Clason ER, Domínguez D, Rebutti GM, Mancia CM, López RT, Meza MR, López DT, Muñoz Zambrano JJ, Herrera EL, Dina-Batlle E, Terrones MC, de Moraes TP, Yánez TR, Osorio W, Cabeza AA, Rico-Fontalvo J. Efficacy and safety of finerenone in diabetic kidney disease: Latin American experience from FINDKDLATAM trial. World J Nephrol 2026; 15(1): 115933
URL: https://www.wjgnet.com/2220-6124/full/v15/i1/115933.htm
DOI: https://dx.doi.org/10.5527/wjn.v15.i1.115933

Arnedo RD, Polo VS, Garcia JB, Gutiérrez JF, Clason ER, Domínguez D, Rebutti GM, Mancia CM, López RT, Meza MR, López DT, Muñoz Zambrano JJ, Herrera EL, Dina-Batlle E, Terrones MC, de Moraes TP, Yánez TR, Osorio W, Cabeza AA, Rico-Fontalvo J. Efficacy and safety of finerenone in diabetic kidney disease: Latin American experience from FINDKDLATAM trial. World J Nephrol 2026; 15(1): 115933 [PMID: 41884241 DOI: 10.5527/wjn.v15.i1.115933]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.